Clinical Performance of Technetium-99m–Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice
2023; Lippincott Williams & Wilkins; Volume: 210; Issue: 3 Linguagem: Inglês
10.1097/ju.0000000000003557
ISSN1527-3792
AutoresJared Schober, Avery Braun, Kevin Ginsburg, Spencer Bell, Alberto Andres Castro Bigalli, Michelle Chen, Robert Wang, Diana Magee, Laura Bukavina, Elizabeth Handorf, Jian Q. Yu, David Y.T. Chen, Richard E. Greenberg, Marc C. Smaldone, Rosalia Viterbo, Andres F. Correa, Robert G. Uzzo, Alexander Kutikov,
Tópico(s)Advanced X-ray and CT Imaging
ResumoTechnetium-99m-sestamibi single-photon emission CT/x-ray CT is an emerging clinical tool to differentiate oncocytic tumors from renal cell carcinomas. We report data from a large institutional cohort of patients who underwent technetium-99m-sestamibi scans during evaluation of renal masses.
Referência(s)